{"id":117561,"date":"2023-05-09T15:28:49","date_gmt":"2023-05-09T19:28:49","guid":{"rendered":"https:\/\/v2fr5er78d.funnewsdaily.com\/books\/epilepsy-drugs-market-is-expected-to-reach-9-8-billion-by-2032-allied-market-research\/"},"modified":"2023-05-09T15:28:49","modified_gmt":"2023-05-09T19:28:49","slug":"epilepsy-drugs-market-is-expected-to-reach-9-8-billion-by-2032-allied-market-research","status":"publish","type":"post","link":"https:\/\/v2fr5er78d.funnewsdaily.com\/books\/epilepsy-drugs-market-is-expected-to-reach-9-8-billion-by-2032-allied-market-research\/","title":{"rendered":"Epilepsy Drugs Market Is Expected to Reach $9.8 Billion by 2032: Allied Market Research"},"content":{"rendered":"

<\/p>\n

\n

The factors that drive the growth of the global epilepsy drugs market are the rise in the prevalence of epilepsy, the growing awareness about epilepsy and its treatment options among people, an increase in the number of healthcare professionals, the rise in the geriatric population, and the rise in initiatives by non-government and government organizations to increase awareness about epilepsy among patients through different programs and campaigns.<\/h2>\n

\/EIN News<\/a>\/ — Portland, OR, May 05, 2023 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global epilepsy drugs market<\/u><\/a> generated $7 billion in 2022, and is estimated to reach $9.8 billion by 2032, witnessing a CAGR of 3.5% from 2023 to 2032.<\/b> The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.<\/p>\n

Request Sample Report- https:\/\/www.alliedmarketresearch.com\/request-sample\/1497<\/u><\/a> <\/b><\/p>\n

Report coverage & details:<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Report Coverage<\/b> <\/td>\n Details<\/b> <\/td>\n<\/tr>\n
Forecast Period <\/td>\n 2022\u20132032 <\/td>\n<\/tr>\n
Base Year <\/td>\n 2022 <\/td>\n<\/tr>\n
Market Size in 2022 <\/td>\n $7 Billion <\/td>\n<\/tr>\n
Market Size in 2032 <\/td>\n $9.8 Billion <\/td>\n<\/tr>\n
CAGR <\/td>\n 3.5% <\/td>\n<\/tr>\n
No. of Pages in Report <\/td>\n 290 <\/td>\n<\/tr>\n
Segments Covered <\/td>\n Seizure Type, Drugs Generation, Distribution Channel, and Region <\/td>\n<\/tr>\n
Drivers <\/td>\n The rise in the prevalence of epilepsy <\/td>\n<\/tr>\n
The growing awareness about epilepsy and its treatment options among people and an increase in the number of healthcare professionals\u00a0 <\/td>\n<\/tr>\n
Th rise in the geriatric population which is more prone to develop epileptic conditions <\/td>\n<\/tr>\n
Opportunities <\/td>\n The rise in initiatives by non-government and government organizations to increase awareness about epilepsy among patients through different programs and campaigns <\/td>\n<\/tr>\n
Restraints <\/td>\n Limited access to healthcare services, especially in rural or underserved areas can hinder the diagnosis and treatment of epilepsy, leading to reduced demand for epilepsy drugs <\/td>\n<\/tr>\n<\/table>\n

Covid-19 Scenario:<\/b><\/p>\n